At CES 2026, Withings has once again pushed the boundaries of consumer health technology with the unveiling of its latest smart scale, the Body Scan 2. Priced at USD 599.95 and positioned as a comprehensive "longevity station," this device aims to transform a simple daily ritual into a deep dive into cardiovascular and metabolic health, tracking over 60 biomarkers in just 90 seconds. This launch represents a significant step in the company's vision to make advanced, non-invasive health monitoring a seamless part of everyday life.
Key Specifications & Data: Withings Body Scan 2
- Price: USD 599.95
- Launch Target: Q2 2026 (US, pending FDA clearance)
- Key Features:
- Tracks 60+ biomarkers in a 90-second assessment.
- 12 electrodes total (8 on platform, 4 in retractable handle).
- Technologies: 6-lead ECG, Impedance Cardiography (ICG), Pulse Wave Velocity, Bioimpedance Spectroscopy (BIS), foot sweat analysis.
- Health Trajectory Score synthesizes data into a single healthspan metric.
- Eyes-Closed Mode displays emojis instead of numbers.
- Regulatory & Compliance: Seeking FDA clearance for hypertension and ECG features; will be GDPR/HIPAA compliant with ISO 27001 & 27701 certifications.
- Battery: Rechargeable, lasts up to 15 months.
The Evolution of the Smart Scale
The Body Scan 2 builds upon the foundation of its predecessor, retaining the innovative design that includes eight electrodes on the scale platform and an additional four within a retractable handle. This design is crucial, as it allows the device to capture upper-body data through the handle, providing a more complete and accurate picture of body composition than scales that rely solely on foot electrodes. The major leap forward with this new model lies in the sheer volume and sophistication of the health data it collects, moving far beyond simple weight and body fat percentage.
A Deep Dive into Biomarkers and the "Health Trajectory"
The core promise of the Body Scan 2 is its 90-second "longevity assessment." This comprehensive check-up breaks down into five key categories: heart pumping performance and electrical activity, hypertension risk, artery health, cellular health and metabolic efficiency, and glycemic regulation. To prevent users from being overwhelmed by tracking over 60 individual metrics, Withings introduces a synthesized "Health Trajectory" score. This single, digestible number is designed to visualize a user's healthspan—the expected years of good health—offering a clear, high-level indicator to follow over time.
Non-Invasive Metabolic Health Tracking
One of the most intriguing technological aspects of the Body Scan 2 is its approach to metabolic health. Instead of relying on periodic blood tests, the scale uses bioimpedance spectroscopy (BIS) and an analysis of foot sweat. BIS sends electrical currents at different frequencies to assess cell membrane health. The foot sweat analysis involves stimulating sweat glands with a tiny current to measure their activity, which can serve as an early indicator of issues like poorly controlled diabetes. Antoine Joussain, Withings' director of product management, emphasizes that these methods allow for frequent, easy tracking, though they are intended as wellness flags, not diagnostic tools.
Navigating Emotional and Regulatory Hurdles
Withings is acutely aware that scales can be emotionally charged devices. To address potential issues with body dysmorphia or disordered eating, the Body Scan 2 features an "Eyes-Closed Mode." In this mode, the scale's display shows only emojis, while all measurements are silently recorded in the accompanying app, allowing users to track progress without fixating on daily numbers. On the regulatory front, the scale's hypertension risk notifications and six-lead EKG for atrial fibrillation detection will require FDA clearance. Withings is pursuing a new certification path to expedite this process, aiming for a Q2 2026 release in the US. The device will also be compliant with GDPR, HIPAA, and include ISO privacy and security certifications.
Positioning in a Competitive Market
The Body Scan 2 enters a market where companies like Whoop and Oura are also developing sophisticated healthspan and cardiovascular age metrics. Withings differentiates itself by consolidating this advanced tracking into a single, stationary device that many people already use daily. The argument is one of convenience and comprehensiveness: capturing a wide array of data in one 90-second session. However, its success will hinge on the accuracy of its non-invasive methods, the speed of regulatory approval, and its ability to convince consumers that a smart scale can be a central pillar for proactive, long-term health management.